Overview

A Phase 2 Study of VS-6766 Plus Defactinib

Status:
Not yet recruiting

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer.

Phase:

Phase 2

Details

Lead Sponsor:

University of Oklahoma

Collaborator:

Verastem, Inc.